Cabaletta Bio, Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following article that they exploit animals for product testing.
“Dr. Payne’s laboratory pioneered the CAAR T cell therapy concept for targeted depletion of autoreactive B cells and conducted the preclinical proof-of-concept work that demonstrated that DSG3 CAAR T cells could robustly control the disease in an animal model, which was published in Science (353: 179-184, 2016).” Read the full article
Company Website: https://cabalettabio.com